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The aims of this phase I/II study of docetaxel and S-1 were to determine the dose-limiting toxicity (DLT), maximum-tolerated dose
(MTD), and recommended dose (RD) in the phase I part and to explore the tumour response, survival and safety in the phase II part.
Patients with histologically- or cytologically confirmed unresectable or recurrent gastric cancer were eligible. Treatment consisted of
intravenous docetaxel on day 1 (starting dose 50mgm
 2) and oral S-1 at a fixed dose of 40mgm
 2 twice daily on days 1–14, every
4 weeks up to six cycles. Nine patients took part in the phase I portion of the study. The MTD of docetaxel was determined to be
50mgm
 2, with the DLTs of grade 3 infection associated with grade 3 neutropenia and grade 4 neutropenia during S-1
administration. The RD of docetaxel was 40mgm
 2 in combination with S-1 40mgm
 2 b.i.d. The efficacy and safety of this regimen
was therefore assessed in 46 patients with at least one measurable lesion. The overall response rate and estimated median overall
survival were 46% (95% CI, 31–61%) and 14.0 months (8.3–17.3 months), respectively. The most common grade 3/4 toxicity was
neutropenia (67% of patients), which was predictable and manageable. This regimen showed promising activity with moderate
toxicities in advanced gastric cancer.
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Although the incidence of gastric cancer (GC) has been declining,
it remains one of the most common causes of cancer-related
deaths (Jemal et al, 2005). Surgical resection at the early stage of
disease is considered the most important intervention that leads to
long-term disease-free survival, but many patients have recur-
rences or are diagnosed with more advanced stages of disease. For
such patients, 1-year survival rates are approximately 50% in stage
III disease, and o25% in stage IV disease (Alberts et al, 2003).
Thus, considerable attention has been paid to the development of
effective treatment for patients with advanced GC.
Cytotoxic chemotherapy including 5-fluorouracil (5-FU) is the
most effective means of providing survival benefits and improve-
ments in quality of life compared with best supportive care
(Wo ¨hrer et al, 2004). However, these improvements have been
modest, at best, and thus far no combination has clearly provided
a survival advantage over single agent 5-FU (Ohtsu, 2005). There-
fore, although no accepted global standard regimen has been
established, most physicians rely on 5-FU as monotherapy or as
part of a combination strategy.
Docetaxel (Taxotere
s, sanofi-aventis, Paris, France) is a semi-
synthetic taxoid derived from the European yew tree, Taxus baccata
(Denis et al, 1990). A preclinical study of docetaxel showed a
synergistic antitumour activity in combination with 5-FU (Bissery
et al, 1995), which led to several clinical studies in advanced GC.
In this setting, docetaxel has been evaluated both as a single agent
(Sulkes et al, 1994; Einzig et al, 1996; Taguchi et al, 1998; Mai et al,
1999) and in combination with fluoropyrimidines (Constenla et al,
2002; Park et al, 2004), cisplatin (Roth et al, 2000), and cisplatin
plus 5-FU (Van Custem et al, 2003). In a randomised phase III
study, this latter regimen (TCF) improved overall survival com-
pared to cisplatin plus 5-FU (Moiseyenko et al, 2005). The doce-
taxel containing combination regimens are associated with severe
leucopenia and febrile neutropenia, and although these adverse Received 22 March 2006; revised 3 May 2006; accepted 3 May 2006
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sevents can be managed, efforts must be made to minimise such
toxicities (Sulkes et al, 1994; Einzig et al, 1996; Taguchi et al, 1998;
Mai et al, 1999).
The anticancer drug S-1 (TS-1
s, Taiho Pharmaceutical Co. Ltd.,
Tokyo, Japan) is an oral formulation containing within each capsule
tegafur, a 5-FU prodrug; gimeracil, an inhibitor of dihydropyri-
midine dehydrogenase; and oteracil, which inhibits pyrimidine
phosphoribosyl transferase specifically in the gastrointestinal tract
and thereby decreases the phosphorylation of 5-FU in the intestine
(Shirasaka et al, 1996). Phase II studies of S-1 monotherapy in
patients with advanced GC showed overall response rates (ORRs) of
26–49% with the most relevant side-effects being diarrhoea in a
European study and neutropenia in two Japanese studies (Sakata
et al, 1998; Koizumi et al, 2000; Chollet et al, 2003).
Based on the clinical activity of both docetaxel and S-1, as well
as the promising efficacy of docetaxel when combined with other
fluoropyrimidines, we conducted a phase I/II study of docetaxel
and S-1 in order to develop an effective treatment for patients with
advanced GC that would improve on the safety profile of earlier
taxane-fluoropyrimidine combinations.
MATERIALS AND METHODS
Study design
This was a multicentre, open-label, single-arm, phase I/II study
conducted at 16 institutions in Japan. The objective of the phase I
part was to determine the dose-limiting toxicity (DLT), maximum-
tolerated dose (MTD) and recommended dose (RD) of docetaxel
combined with a fixed dose of S-1. In the phase II part, the primary
objective was to estimate the ORR of this combination at the RD.
Secondary objectives were to assess progression-free survival,
overall survival, 1-year survival rate, and adverse events. This
study was conducted in accordance with the principles of the
Declaration of Helsinki and Good Clinical Practice guidelines.
The study protocol was reviewed and approved by the institutional
review board of each participating centre. The objective response
was independently reviewed by the extramural review committee,
and the MTD and RD were determined by the independent data
monitoring committee.
Patients
Patients were eligible if they signed informed consent and met
all the following criteria: histologically- or cytologically confirmed
unresectable or recurrent GC; at least one measurable lesion
(patients without a measurable lesion, but evaluable nonmeasur-
able lesions were permitted in the phase I part of this study);
Eastern Cooperative Oncology Group performance status of 0–1;
good recovery from surgery (at least 28 days after the operation);
up to one prior chemotherapy regimen except for prior taxane
(paclitaxel or docetaxel) or S-1 (other fluoropyrimidines were
allowed if at least 28 days elapsed after the last treatment); X20
years of age; estimated life expectancy of at least 3 months;
haemoglobin X8.0gdl
 1; white blood cell count between 4000 and
12000mm
 3; neutrophil count X2000mm
 3; platelet count
X100000mm
 3; serum bilirubin p1.5mgdl
 1; aspartate amino-
transferase and alanine aminotransferase p2.5 times the upper
limit of normal (ULN); and serum creatinine less than or equal
to ULN.
Exclusion criteria were as follows: pregnant female or sexually
active males/females unwilling to use contraception during the
study; infection or suspected infection with fever; congestive heart
failure; uncontrolled angina pectoris or arrhythmia; a history of
myocardial infarction within the previous 3 months; uncontrolled
diabetes or hypertension; interstitial pneumonia or lung fibrosis;
peripheral neuropathy grade 2 or higher; pleural, peritoneal, or
pericardial effusion that required treatment; gastrointestinal
haemorrhage; symptomatic brain metastasis; diarrhoea; and active
concomitant malignancy.
Phase I part
Patients received variable doses of intravenous docetaxel adminis-
tered as a 1–2-h infusion on day 1 and oral S-1 administered at
a fixed dose of 40mgm
 2 twice daily on days 1–14 every 4 weeks
(one cycle). Patients were treated for up to six cycles unless disease
progression or unacceptable toxicity was observed.
The initial starting dose of docetaxel was 50mgm
 2 (dose level
1), and step-wise dose increases to 60 and 70mgm
 2 were planned
for successive patient cohorts (dose levels 2 and 3, respectively). In
the case that dose level 1 was not acceptable, docetaxel 40mgm
 2
(dose level 0) would be explored.
At least three patients were to be started at dose level 1. If
all three patients experienced DLTs, this dose level was determined
to be the MTD, and dose level 0 would be explored. If two or fewer
patients had DLT, an additional three patients were to be treated
at the same dose level. If three or more than six patients treated
at dose level 1 had DLTs, this dose level was determined to
be the MTD, and dose level 0 would be explored. Dose escalation
was planned until the MTD was reached, in which case the next
lower dose level would be considered for further evaluation in the
phase II part of the study. If three or more patients treated at
dose level 0 experienced DLT, the regimen would be deemed not
feasible.
Dose-limiting toxicitys were defined as follows: (1) grade 4
neutropenia lasting for 5 days or longer; (2) grade 4 neutropenia
with fever (X38.51C); (3) grade 4 thrombocytopenia; (4) grade 3/4
nonhaematological toxicities other than nausea/vomiting,
anorexia, and general fatigue; and (5) any grade 4 haematological
toxicity during S-1 administration. Assessment of DLTs was
conducted only in the first treatment cycle. An independent data
monitoring committee evaluated the safety results for each dose
level and determined the MTD and RD.
Phase II part
Study treatment Patients received the combination treatment
with the RD of docetaxel on day 1 and oral S-1 40mgm
 2 twice
daily in accordance with the treatment regimen described above.
Cycles were repeated every 4 weeks for up to six cycles unless
disease progression or unacceptable toxicity was observed. The
protocol did not specify rules for interruption and resumption of
S1 within each cycle. Such decisions were based on the clinical
judgment of the investigator.
Chemotherapy was withheld for the following toxicities: (1)
neutrophil count o1500mm
 3 or platelet count o100000mm
 3;
(2) aspartate aminotransferase or alanine aminotransferase 42.5
times ULN, or total serum bilirubin 41.5mgdl
 1; (3) body
temperature X381C; (4) performance status X2; (5) diarrhoea
grade 2 or more; (6) neuropathy grade 2 or more; (7) oedema
grade 2 or more. Treatment was restarted after recovery to
baseline. If patients did not recover from these toxicities within 28
days of the last administration of S-1, they were withdrawn from
the study.
If any of the following toxicities was observed, the dose of
docetaxel was reduced by one level (phase I part) or by 10mgm
 2
(phase II part): (1) grade 3/4 neutropenia with fever (438.51C);
(2) haemorrhage with grade 3/4 thrombocytopenia or requirement
for a platelet transfusion; and (3) grade 3/4 nonhaematological
toxicity other than nausea/vomiting, anorexia, general fatigue, and
hypersensitivity. The dose of S-1 could be reduced by 20mg per
day if any of these toxicities were observed after the dose reduction
of docetaxel or the RD was determined to be level 0.
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sSupportive care Throughout this study, the prophylactic admin-
istration of granulocyte colony-stimulating factor (G-CSF), anti-
emetic agents, corticosteroids including premedication to
docetaxel, or antihistamines was not allowed during the first
treatment cycle. Use of these agents was allowed as secondary
prevention of symptoms in all subsequent cycles.
Outcome measures Tumour response was assessed according to
the Response Evaluation Criteria in Solid Tumors (Therasse et al,
2000). Assessments by imaging studies were repeated every 4
weeks during the study. Progression-free survival was defined as
the time from registration until objective tumour progression or
death (censored at second-line chemotherapy) and overall survival
was defined as the time from registration until death from any
cause (censored at the time of last visit in patients who were lost to
–follow up). Progression-free and overall survival, and 1-year
survival rates were estimated using the Kaplan–Meier method.
Adverse events were graded according to the National Cancer
Institute Common Toxicity Criteria (version 2). Haematological
and biochemical tests, performance status and clinical assessment
of symptoms were monitored at least every week in the phase I
part and every 2 weeks in the phase II part. The relative dose
intensity (DI) was calculated as follows: actual DI¼total dose
(mgm
 2)/treatment period (weeks); planned DI (PDI)¼originally
planned cumulative dose in the first course (mgm
 2)/4 weeks; and
relative DI¼DI/PDI.
Statistical methods The design of this study was based on a
binominal distribution with no planned interim analysis. For the
phase II part of this study, the primary end point was to determine
the ORR. Assuming a null hypothesis of a 35% ORR and an
alternative hypothesis of a 55% ORR, with one-sided type I
error¼0.05 and type II error¼0.2, it was necessary to enrol a
minimum 45 patients at the RD, including those treated at the RD
during the phase I part of the study. All analyses were performed
using SAS
s version 8.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Between September 2002 and June 2004, a total of 50 patients were
enrolled into the study. Nine patients (three in level 1 and six in
level 0) were enrolled into the phase I part and 41 patients into the
phase II part. Of the 41 patients enrolled into the phase II part of
the study, one patient did not receive either docetaxel or S-1
because her disease had progressed rapidly and she could not take
drugs orally before the initiation of treatment. This patient was
excluded from all analyses according to the Full Analysis Set
principle. Therefore, the population evaluable for efficacy and
safety in the phase II analysis included six patients treated at the
RD during the phase I part and 40 patients treated during the
phase II part of the study.
Phase I part
The first cohort of three patients received docetaxel 50mgm
 2
combined with S-1 40mgm
 2 twice daily (dose level 1). Among
these patients, one experienced grade 3 infection associated with
grade 3 neutropenia on day 11, and two had grade 4 neutropenia
on day 8 during S-1 administration. As all three patients treated at
dose level 1 were deemed to have a DLT, the next cohort of patients
was treated at dose level 0 (docetaxel 40mgm
 2). A total of six
patients received 1–6 cycles of treatment at level 0. Among these,
only one developed a DLT (grade 3 infection without neutropenia).
From these results, the MTD and RD were determined to be level 1
and level 0, respectively.
Phase II part
Patients Baseline characteristics of the 46 patients treated at the
RD are shown in Table 1. Median age was 65 years (range, 42–79).
All patients had at least one measurable lesion. Thirty-four
patients (74%) had primary gastric lesions. Twenty-two patients
(48%) had hepatic metastases. Sixteen patients (35%) had received
a prior chemotherapy including 5-FU-containing regimens,
irinotecan plus cisplatin or oral fluoropyrimidines.
Study treatment A total of 165 cycles were administered, with
a median of three cycles (range, 1–6). The median cumulative
doses of docetaxel and S-1 were 120mgm
 2 (range, 40–240) and
3098mgm
 2 (range, 204–6368), respectively. Median relative dose
intensities of docetaxel and S-1 were 99% (range, 75–101) and 82%
(range, 18–97), respectively. Thirty-six patients (78%) who failed
study treatment received the next-line chemotherapy. The main
regimen was cisplatin plus irinotecan (17/36, 47%).
Efficacy Tumour response results are shown in Table 2. The ORR
was 46% (95% confidence interval ((CI), 31–61) with two patients
(4%) showing a complete response and 19 (41%) a partial
response. Figure 1 shows overall and progression-free survival.
At a median follow-up of 12 months (range, 2–27), the median
progression-free and estimated overall survival times were 4.2
months (95% CI, 2.2–5.2) and 14 months (95% CI, 8.3–17.3),
respectively. The 1-year survival rate was 53% (95% CI, 38–67).
Safety Table 3 summarises adverse events observed during the
phase II part of this study. The most common grade 3/4 haemato-
logical toxicities were neutropenia (31 patients, 67%) and
Table 1 Baseline characteristics of 46 patients* in the phase II part
Characteristic Number of patients (%)
Sex
Male 31 (67)
Female 15 (33)
ECOG performance status
0 29 (63)
1 17 (37)
Histology
Intestinal 29 (63)
Diffuse 17 (37)
Metastatic sites
Lymph nodes 35 (76)
Liver 22 (48)
Ovary 1 (2)
Spleen 1 (2)
Rectum 1 (2)
Adrenal gland 1 (2)
Gastric remnant 1 (2)
No of metastatic sites
1 31 (67)
2 14 (30)
3 1 (2)
Prior therapy
None 25 (54)
Any prior therapy 21 (46)
Surgery 13 (28)
Chemotherapy 16 (35)
ECOG¼Eastern Cooperative Oncology Group. *Six patients treated at the
recommended docetaxel dose of 40mgm
 2 in the phase I part were included in
analysis.
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median time from the treatment start to nadir was 14 days (range,
3–29) and the median time from nadir to recovery was 15 days
(range, 2–27). The study treatments were delayed for the following
reasons: neutropenia (6/165 cycles, 4%), thrombocytopenia (3/165,
2%), worsening of PS (2/165, 1%), and fever (1/165, 1%). The doses
of S-1 were reduced in 16 patients (35%) mainly due to grade 4
neutropenia and grade 3 anorexia. Treatment with G-CSF as
secondary prophylaxis for neutropenia was administered in 23
cycles (14%). The most common grade 3/4 nonhaematological
toxicity was anorexia (10 patients, 22%). Fever and infection were
observed in 10 patients (22%, grade 1 or 2) and two patients (4%,
all grade 3), respectively. Oedema (grade 1) was observed in only
three patients (7%), despite the absence of prophylactic cortico-
steroids or antihistamines. The majority of the nonhaematological
toxicities were relatively mild. No treatment-related deaths were
observed.
In five patients, combination treatment was discontinued due to
the following adverse events: grade 4 neutropenia associated with
grade 3 diarrhoea, grade 4 neutropenia associated with grade 2
thrombocytopenia, grade 3 neutropenia associated with unrecov-
ered grade 2 anaemia, grade 4 cerebral infarction, and suspected
grade 2 interstitial pneumonia.
DISCUSSION
We evaluated the efficacy and safety of a chemotherapy combina-
tion regimen of docetaxel and S-1, two agents that separately have
shown promise in the management of advanced GC. Response
rates and safety data for S-1 have shown ORRs up to 49% with
no grade 4 haematological toxicity (Sakata et al, 1998; Koizumi
et al, 2000), while adding docetaxel to a standard chemotherapy
regimen of cisplatin and 5-FU improves survival (TAX 325,
Moiseyenko et al, 2005). Therefore, our hypothesis was that
docetaxel combined with S-1 would confer a clinically meaningful
improvement in ORR and median survival, with a manageable
safety profile.
In the phase I part of our study, we identified docetaxel
40mgm
 2 on day 1 plus S-1 40mgm
 2 twice a day on days 1–14,
every 28 days as the treatment schedule to recommend for further
clinical evaluation. This dose of docetaxel is lower than that
commonly used in the West to treat GC. However, we observed
severe myelosuppression at dose level 1 (docetaxel 50mgm
 2),
which was the MTD. In this study, the MTD was declared when all
of the first three patients in a cohort experienced DLT or when at
least three of six patients enrolled in a cohort experienced DLT.
Although this definition differs from that employed in other
studies, it is commonly accepted in Japan. Our use of this
definition allowed us to find a RD that was tolerable for most
patients enrolled in the phase II portion of this study.
We speculate the reason for the lower dose of docetaxel may be
that the pharmacokinetic parameters (AUC and Cmax) of 5-FU
increase according to the dose of docetaxel. For example, the
respective mean AUC and Cmax of 5-FU were 522.5nghml
 1 and
100.3ngml
 1 with docetaxel 40mgm
 2 and 857.2nghml
 1 and
155.8ngml
 1, with docetaxel 50mgm
 2 (Yoshida et al, 2004).
Synergy of this combination has been reported in vitro, suggesting
that biochemical modulation of the two drugs occurs. This synergy
may also result in increased toxicity (Wada et al, 2006). Perhaps
higher doses of docetaxel would have conferred a greater response
rate, but such doses were not feasible in our study population.
Preliminary reports have described alternative dosing schedules
for docetaxel in combination with S1 for the treatment of advanced
GC. These have explored docetaxel dosing intervals ranging from
every week to every 4 weeks with relative dose intensities from 10
to 20mgm
 2 per week. However, because final reports of these
studies are not yet available, the feasibility and efficacy of these
alternative regimens remains unknown (Yoshida et al, 2004; Kim
et al, 2006; Park et al, 2006; Rino et al, 2006; Satoh et al, 2006;
Takahashi et al, 2006).
Table 2 Tumour responses in the phase II part
N Response rate (%)
Total 46 46
a
Sub-group analyses by
Age
o65 23 43
65p 23 48
Histology
Intestinal 29 41
Diffuse 17 53
Prior chemotherapy
Not received 30 50
Received 16 38
Liver metastasis
Absent 24 67
Present 22 23
a95% confidence interval¼31–61%.
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Figure 1 The cumulative probability of survivals. The solid and dotted
lines present overall and progression-free survivals estimated by the
Kaplan–Meier method in 46 patients, respectively.
Table 3 Adverse events observed in 46 patients
Number of patients grade
a
Adverse events 3 4
Number of patients(%)
grade 3 or 4
Neutropenia 15 16 31 (67)
Leucopenia 16 3 19 (41)
Anaemia 9 1 10 (22)
Anorexia 10 0 10 (22)
Hyponatremia 8 0 8 (17)
Nausea 4 0 4 (9)
Vomiting 1 0 1 (2)
Stomatitis 3 0 3 (7)
Diarrhoea 2 0 2 (4)
AST elevation 3 0 3 (7)
Infection 2 0 2 (4)
AST¼aspartate aminotransferase.
aNational Cancer Institute common toxicity
criteria (version 2).
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patients with advanced GC, this regimen conferred an ORR of 46%
and an estimated median survival of 14 months, with acceptable
toxicity. The 46% ORR observed in this study was slightly lower
than expected. We anticipated an ORR of 55% because results from
phase II studies in Japan showed ORRs of 22% with docetaxel
monotherapy (Taguchi et al, 1998; Mai et al, 1999) and 45% with
S-1 (Sakata et al, 1998; Koizumi et al, 2000). A possible explana-
tion is that we included a significant number of patients with
liver metastasis (22/46, 47.8%) and intestinal-type histology (29/46,
63%), and many had previous exposure to chemotherapy (16/46,
34.8%). All of these features are associated with decreased
response rates to chemotherapy (Taguchi et al, 1998, Mai et al,
1999, Koizumi et al, 2000, Ajani et al, 2005). Yet despite these
unfavourable baseline characteristics, the combination of
docetaxel and S-1 conferred an ORR that was similar to those
obtained with other combination regimens (Ajani et al, 2005;
Thuss-Patience et al, 2005).
At a median follow-up of 12 months, the median overall survival
was estimated to be 14 months. Although cross-study comparisons
should be taken with caution, the survival effect observed in our
study compares favourably with other chemotherapy regimens,
such as docetaxel (6–8 months (Taguchi et al, 1998; Mai et al,
1999)) or S-1 (7–8 months (Sakata et al, 1998; Koizumi et al,
2000)), or the combinations DC (11 months), DF (10 months), DCF
(10 months), ECF (10 months) or FOLFOX-4 (11 months) (Ajani
et al, 2005; De Vita et al, 2005; Thuss-Patience et al, 2005).
Patients enrolled in our study were, in some respects, less likely
to respond to chemotherapy than patients in these other trials. All
patients in our study had metastatic disease, 65% were chemo-
naive, and 48% had liver metastases. In studies of DCF, ECF, and
FOLFOX-4, the proportions of chemo-naive patients were 100, 100,
and 84%, respectively; the rates of metastatic disease were 95, 98,
and 92%, respectively; and the incidences of liver metastases were
80% (including peritoneal), 36, and 62%, respectively. Despite this,
the ORR and survival observed in our study appeared higher than
those reported for other combination regimens studied in more
favourable populations. At a median follow-up of 12 months, the
estimated median survival is 14 months, but this may improve
over time.
Although survival data appear promising, there are limitations.
Progression-free survival in this study was similar to those repor-
ted with conventional reference regimens containing 5-FU and
cisplatin (Vanhoefer et al, 2000; Ohtsu et al, 2003). In addition, the
median survival observed in our study may be partly influenced
by poststudy chemotherapy, which was administered to 78% of
patients.
The docetaxel/S1 regimen reported here was well tolerated and
toxicities were manageable. The most common haematological
toxicities were neutropenia and leucopenia. The incidence of grade
3/4 neutropenia was similar to those previously reported with
docetaxel monotherapy (Sulkes et al, 1994; Einzig et al, 1996;
Taguchi et al, 1998; Mai et al, 1999). Despite the lack of cortico-
steroid prophylaxis, only three patients developed fluid retention
(all grade 1), and no patients had a hypersensitivity reaction. The
majority of nonhaematological toxicities were mild.
The docetaxel/S1 regimen used in this study yielded a promising
median survival time and manageable safety profile. Based partly
on these results, a phase III study comparing S-1 alone to docetaxel
plus S-1 in patients with advanced GC has begun enrolment in
Japan to evaluate whether adding docetaxel to S1 improves clinical
benefit.
In conclusion, the combination of docetaxel and S-1 is an active
and well-tolerated regimen in patients with advanced GC. It is
worthwhile to assess the survival benefit and quality of life in a
phase III trial of this combination in advanced GC to establish the
new regimen for the outpatient setting.
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